Mega Lifesciences reports 33.1 percent profit growth for Mega Lifesciences stock

Published on 10/20/2026 at 01:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half revenue grew 12.5 percent and reported profit 33.1 percent. Mega Lifesciences stock heads to November 12, 2026 Q3 results.

Earnings calendar and analyst view

Reported net profit grew 33.1 percent in the first half of 2026.
Overall operating revenue increased 12.5 percent year over year in the first half of 2026.
Mega Lifesciences stock was last at THB 32.75 on October 19, 2026.
Finam set a THB 44.60 12-month target on October 15, 2026.

Mega Lifesciences stock, healthcare, first-half 2026 results, analyst target, SET, Illustration mit AI erstellt.

Mega Lifesciences reported 33.1 percent growth in first-half 2026 net profit, while its stock was last at THB 32.75 on October 19, 2026. Mega Lifesciences lists the figures and the next quarterly reporting date in its investor calendar.

Profit growth outpaced revenue

The company said overall operating revenue grew 12.5 percent year over year in the first half of 2026. Reported net profit increased 33.1 percent, adjusted net profit rose 11.7 percent and EBITDA advanced 33.8 percent in the same period, according to the investor-relations update.

The second-quarter comparison shows why margins are central to the story. Simply Wall St reported Q2 2026 revenue of THB 3,547.183 million, versus THB 3,420.07 million in Q2 2025. Net income excluding extra items reached THB 514.611 million, compared with THB 390.918 million a year earlier, while net margin rose from 11.4 percent to 14.5 percent.

What comes next for earnings?

Mega's investor calendar schedules the third-quarter earnings announcement for November 12, 2026 and the conference call for November 13, 2026. The company also lists an earnings call for December 1, 2026, giving investors three dated checkpoints after the first-half figures.

What does the valuation imply?

On October 15, 2026, Finmarket reported that Finam assigned a Buy rating and a 12-month target of THB 44.60. The same report linked the potential to branded products in Asia and Africa and to logistics efficiency. A separate risk marker is the THB 2.6 billion to THB 2.7 billion capital-expenditure plan described by Simply Wall St, which places execution and cash conversion alongside the profit-growth figures.

Stock price and trading calendar

Mega Lifesciences was last at THB 32.75 on the Stock Exchange of Thailand on October 19, 2026 at 4:36 p.m. ICT. The quoted 52-week range was THB 28.25 to THB 40.00, and market capitalization was THB 28.6 billion as of the same date. The company operates across branded health products, pharmaceutical distribution and contract manufacturing.